Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma.
about
Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocolsStaging of hepatocellular carcinomaBarcelona Clinic Liver Cancer outperforms Hong Kong Liver Cancer staging of hepatocellular carcinoma in multiethnic Asians: Real-world perspective.CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging featuresSafety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis.Upregulation of heat shock proteins (HSPA12A, HSP90B1, HSPA4, HSPA5 and HSPA6) in tumour tissues is associated with poor outcomes from HBV-related early-stage hepatocellular carcinoma.Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients.A comparison of clinical manifestations and prognoses between patients with hepatocellular carcinoma and Child-Pugh scores of 5 or 6.Hepatocellular Carcinoma Patients With Performance Status 1 Deserve New Classification and Treatment Algorithm in the BCLC System.Evaluation of eight different clinical staging systems associated with overall survival of chinese patients with hepatocellular carcinoma.Assessment of hemodynamics in a rat model of liver cirrhosis with precancerous lesions using multislice spiral CT perfusion imaging.Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib.Prognosis of Early-Stage Hepatocellular Carcinoma: The Clinical Implications of Substages of Barcelona Clinic Liver Cancer System Based on a Cohort of 1265 PatientsClinical implications of basic research in hepatocellular carcinoma.Nomogram for preoperative estimation of long-term survival of patients who underwent curative resection with hepatocellular carcinoma beyond Barcelona clinic liver cancer stage A1.Radiotherapeutic options for hepatocellular carcinoma with portal vein tumor thrombosisHepatocellular carcinoma and other malignancies in autoimmune hepatitis.Treatment of hepatocellular carcinoma: a systematic review.Staging systems of hepatocellular carcinoma: a review of literature.Hepatocellular carcinoma: surgical perspectives beyond the barcelona clinic liver cancer recommendations.New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions.Staging systems for hepatocellular carcinoma: Current status and future perspectivesAdvances in Local and Systemic Therapies for Hepatocellular Cancer.Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma: A cohort study of the multicenter registry database.Lack of evidence that adherence to standard of care therapy improves survival in subjects with hepatocellular carcinoma in clinical practice.Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the Italian Society of Interventional Radiology.Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies.Applicability of albumin-bilirubin-based Japan integrated staging score in hepatitis B-associated hepatocellular carcinoma.Response to transarterial chemoembolization as a selection criterion for resection of hepatocellular carcinomas.The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients?Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging SystemThe role of autophagy in hepatocellular carcinoma: friend or foe.Adherence to BCLC recommendations for the treatment of hepatocellular carcinoma: impact on survival according to stage.BCLC--now also an internationally acclaimed prognostic system?Conditional survival estimate in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with/without concurrent radiotherapy.Evaluation of seven different staging systems for alpha-fetoprotein expression in hepatocellular carcinoma after hepatectomy.Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus.Epidemiology of liver cancer in South Korea.Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.Incorporating albumin-bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma.
P2860
Q26783881-96DFAFC1-34BF-4956-92B5-2010FF7CFEF5Q28081265-0B165D56-9805-426B-99E4-579CB2387081Q33805894-CBCC0BD3-ACE0-444A-8674-6E209D3AE09FQ34682228-8ADE0025-F55F-4010-B3D2-44172646B76AQ35167764-E85A7D14-811F-420C-9557-2189F76BB2EEQ35197467-6BFFDD38-BC11-4D56-84A7-AE6F062B6DB6Q35225534-052B5167-E922-42BA-8A92-82FEFDE66DD3Q36151682-AE5A0FA4-292A-4273-BCA1-7AA4D905D73FQ36153539-216BA340-AEBC-4E3E-937A-4C7E6AFFBC0EQ36816413-DE7409EA-A569-46E5-9F2F-42630DE1AD40Q36995470-6D0EF3C3-B044-4354-95D3-8239360229B2Q37031750-A3BF6C5A-C48E-490D-A557-E57B7A8F4846Q37176395-06A5B432-6232-4B25-86EE-4FA3D3A51032Q37289933-162C1612-A457-41FC-87DD-C741B7B7A984Q37641616-EE060E1A-757B-4F12-B758-F9E5BB305745Q37716214-9237206A-39F2-49B9-A5FB-EC00A3C773F5Q38073121-85CB4B10-4A86-4C7A-97B5-763F1092F7CEQ38155508-A7CEC78E-AACB-4E15-AE8E-1908A61D2656Q38207014-7ED5C8AD-DB1E-4DF1-A574-87509ADF8913Q38224434-9A33676D-9CD5-49D9-BEC3-C56C69661C3DQ38282800-FC0D85D8-DF72-4041-B3D2-02DDD44D53F5Q38408876-B47514C7-EC6F-4C6A-BF0C-B05141E4F8B6Q38697243-A5E715CD-163B-4231-A53B-D51C8479F88EQ38948642-4EA742AA-E52D-40AC-ABF6-ED4673B988F7Q39035163-148350A8-A930-4B53-838E-9B7DCBFF64F1Q39410889-C2E8001C-F695-4D64-8451-776D669F6C8FQ39458547-460FC5EC-CEB8-4483-BFFB-923FF38FC0AFQ40511264-FF6D004D-C6A3-44DE-99EA-BDFC8669CC78Q40827409-D313CEC4-5E2E-4B4D-9535-8828847B1176Q40875100-F796F515-1874-41C7-BF60-E9D996E3BA9AQ41315716-B9E88CC0-304D-423F-AE34-EA72B9992681Q41339988-8ED44090-4779-4298-801D-7F000F3533B6Q41570050-D07EFCD0-3C08-4CED-B456-BA550F81FE9DQ43440960-C91A3217-C6C6-4151-97FF-8DAA22D11933Q43485596-3D9E09DE-9016-44D0-99DA-D6500F91757CQ43815814-B4777312-E0F5-4FDE-9178-09ED53D52DD2Q47134709-080ED531-D9B6-418B-9648-508869B1A04BQ47564643-5DA7941D-B40D-4B74-9581-01A050E71F5DQ48092299-0F0AF8FE-112A-439D-BD20-63C68347274BQ48214198-17F37A2F-65A8-4F84-BDBC-71A7762BB18F
P2860
Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Applicability of BCLC stage fo ...... with hepatocellular carcinoma.
@en
Applicability of BCLC stage fo ...... with hepatocellular carcinoma.
@nl
type
label
Applicability of BCLC stage fo ...... with hepatocellular carcinoma.
@en
Applicability of BCLC stage fo ...... with hepatocellular carcinoma.
@nl
prefLabel
Applicability of BCLC stage fo ...... with hepatocellular carcinoma.
@en
Applicability of BCLC stage fo ...... with hepatocellular carcinoma.
@nl
P2093
P2860
P1433
P1476
Applicability of BCLC stage fo ...... with hepatocellular carcinoma
@en
P2093
Beom Kyung Kim
Do Youn Lee
Do Young Kim
Eun Hye Kim
Jinsil Seong
Jun Yong Park
Mi Sung Park
Seung Up Kim
P2860
P304
P356
10.1111/J.1478-3231.2012.02811.X
P577
2012-04-23T00:00:00Z